UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.155-163

2009

Volltextzugriff (PDF)

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Clinical pharmacology and therapeutics, 2008-12, Vol.84 (6), p.704-709

2008

Volltextzugriff (PDF)

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

Clinical pharmacology and therapeutics, 2016-06, Vol.99 (6), p.651-660

2016

Volltextzugriff (PDF)

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Clinical cancer research, 2003-08, Vol.9 (9), p.3246-3253

2003

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

Clinical and translational science, 2017-09, Vol.10 (5), p.412-420

2017

Volltextzugriff (PDF)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Clinical and translational science, 2017-07, Vol.10 (4), p.271-279

2017

Volltextzugriff (PDF)

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan

Clinical cancer research, 2005-11, Vol.11 (21), p.7800-7806

2005

Volltextzugriff (PDF)

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

Molecular cancer therapeutics, 2002-05, Vol.1 (7), p.545

2002

Volltextzugriff (PDF)

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.642-650

2012

Volltextzugriff (PDF)

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

Clinical pharmacology and therapeutics, 2011-05, Vol.89 (5), p.693-701

2011

Volltextzugriff (PDF)

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

Clinical cancer research, 2004-12, Vol.10 (24), p.8341-8350

2004

Volltextzugriff (PDF)

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

Clinical cancer research, 2001-08, Vol.7 (8), p.2292-2300

2001

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Journal of clinical oncology, 2006-02, Vol.24 (4), p.552-562

2006

Volltextzugriff (PDF)

Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel

Clinical cancer research, 2001-10, Vol.7 (10), p.3229-3238

2001

Volltextzugriff (PDF)

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Clinical cancer research, 2004-03, Vol.10 (6), p.1976-1983

2004

Volltextzugriff (PDF)

Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

Clinical pharmacology and therapeutics, 2005-01, Vol.77 (1), p.43-53

2005

Volltextzugriff (PDF)

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel

Clinical pharmacology and therapeutics, 2004-05, Vol.75 (5), p.448-454

2004

Volltextzugriff (PDF)

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib

Clinical pharmacology and therapeutics, 2008-03, Vol.83 (3), p.477-484

2008

Volltextzugriff (PDF)

Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

Clinical pharmacology and therapeutics, 2003-10, Vol.74 (4), p.364-371

2003

Volltextzugriff (PDF)

Residual feed intake of purebred Angus steers: effects on meat quality and palatability

Journal of animal science, 2006-04, Vol.84 (4), p.938-945

2006

Volltextzugriff (PDF)

High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9138-9145

2005

Volltextzugriff (PDF)

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

Clinical cancer research, 2005-10, Vol.11 (20), p.7398-7404

2005

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.664-671

2005

Volltextzugriff (PDF)

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

Neuro-oncology (Charlottesville, Va.), 2005-04, Vol.7 (2), p.177-182

2005

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(126)

Sprache

Englisch
(126)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib

Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

Residual feed intake of purebred Angus steers: effects on meat quality and palatability

High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

Aktive Filter

Suchergebnisse filtern